

Minutes of the **Somerset ICS Medicines Optimisation Committee** held via Microsoft Teams, on **Wednesday**, 14<sup>th</sup> April 2021.

Present: Dr Andrew Tresidder Chair, CCG GP Patient Safety Lead

(AT)

Mark Ashley (MA) Chief Pharmacist, Somerset NHSFT Steve Du Bois (SDB) Chief Pharmacist, Somerset NHSFT

Shaun Green (SG) Deputy Director of Clinical Effectiveness and

Medicines Management, CCG

Michael Lennox (ML)
Sam Morris (SM)
Helen Spry (HS)

Tag Talbet White (ZTW)
LPC Representative
Medicines Manager, CCG
Medicines Manager, CCG

Prescribing Tabbaicing CCC

Zoe Talbot-White (ZTW) Prescribing Technician, CCG

Fivos Valagiannopoulos PCN Clinical Pharmacist representative, (FV) South Somerset West PCN & Tone Valley

PCN (LPC rep for independent pharm)

Pamela White (PW) Clinical Pharmacist, YDH NHS FT

Antony Zorzi (AZ) Clinical Pharmacy Manager – acute service

Lead Pharmacist for Antimicrobials,

Somerset NHSFT

Apologies: Andrew Prowse (AP) Chief Pharmacist and Controlled Drugs

Accountable Officer, YDH NHS FT

### 1 INTRODUCTIONS & APOLOGIES FOR ABSENCE

AT welcomed everyone to the Somerset ICS Medicines Optimisation Committee.

Helen Spry, Pamela White, Fivos Valagiannopoulos and Antony Zorzi were introduced to the group.

Apologies were provided as detailed above.

### 2 REGISTER OF MEMBERS' INTERESTS

The Somerset ICS Medicines Optimisation Committee received the Register of Members' Interests relevant to its membership.

There were no amendments to the Register.

The Somerset ICS Medicines Optimisation Committee noted the Register of Members' Interests.

### 3 DECLARATIONS OF INTEREST RELATING TO ITEMS ON THE AGENDA

3.1 Under the CCG's arrangements for managing conflicts of interest, any member making a declaration of interest is able to participate in the discussion of the particular agenda item concerned, where appropriate, but is excluded from the decision-making and voting process if a vote is required. In these circumstances, there must be confirmation that the meeting remains

quorate in order for voting to proceed. If a conflict of interest is declared by the Chairman, the agenda item in question would be chaired by a nominated member of the Somerset ICS Medicines Optimisation Committee.

There were no declarations of interest relating to items on the agenda.

# 4 MINUTES OF THE MEETING HELD ON 10<sup>th</sup> February 2021

4.1 The Minutes of the meeting held on 10<sup>th</sup> February were agreed as a correct record.

### 4.2 Review of action points

Most items were either complete or, on the agenda. The following points were specifically noted:

**Action 1: SIMO Membership-** Fivos attended the meeting today as the representative for PCN pharmacists. It is yet to be decided if Fivos will remain as the sole representative or if the role will be shared with another PCN pharmacist moving forwards.

Action 2: Integration and Pharmacy Transformation Plans-

SG made another plea for Trust feedback on the transformation plan.

# 5 Matters Arising

### 5.1 **Draft TOR**

Currently there is no formal document to present. The decision was made not to bring a Draft TOR to the meeting while we wait for further details on the Somerset system structure (planned YDH NHS FT, Somerset NHSFT merger, white paper and government documents). However we welcome input from members as to what should be included in the TOR.

**Action: All** 

Action: SM & SG

Send TOR suggestions to SG.

Initially SIMO will report to SPF as the line of accountability. However at the moment we are unsure on where SPF will report to going forward. When the new structure is implemented we will know more.

There is concern within the group that SIMO won't have the necessary powers to implement the strategies.

AT has asked that a draft TOR is produced so we can choose to implement it once structures are finalised. It will be a living document that we will develop and evolve to keep us ahead. It will need to reflect the ICS vision and allow us to influence it so we can do what is best for the population of Somerset.

Produce draft TOR for June meeting.

# 5.2 Discuss roles SIMO will take over from SPF eg. Medicines Value, High Cost Drugs, NICE

SPF is recognised as part of the existing governance structure. Members have recognised that it duplicates a lot of things that go to other committees. In setting up this committee there is an opportunity to move aspects so they sit with SIMO not SPF.

SIMO discussed some of the roles they could take over from SPF:

- Financial management
- Benchmarking with medicines optimisation targets
- Local ambitions
- Workforce
- Digital Integrations
- Budget setting and monitoring of high cost drug spend
- NICE clinical areas
- Safety issues

However no decisions were finalised.

Send SG suggestions of what this committee should take from SPF and what the focus of the agenda should be.

Action: All

# 5.3 Integration and Pharmacy Transformation Plans

Not discussed. Leave on agenda for next meeting.

# 5.4 Community Pharmacy Contractual Developments

Not discussed. Leave on agenda for next meeting.

### 5.5 **Somerset Workforce NHSE plan update**

ML shared the good news that the LWAB has decided we have a priority case and will be creating a delivery plan for recruitment, retention and training. They have also found a PMO (Helen Stapleton), who will deliver the project. The first planning meeting is tomorrow and ML will provide SIMO with updates.

SG congratulated ML for his progress with this and added that it needs to be linked in with the business cases for the mental health pharmacists, antimicrobial pharmacist and other necessary clinical pharmacist posts. Workforce is one of the greatest challenges we face.

### 5.6 **Discuss use of regional £10k funding**

This money has been provided to support IPMO programme but we have no use for it as of yet.

It was suggested that the money could be used for recruitment and publicity.

**Action: All** 

Send all suggestions for funding to SG.

# 5.7 **Somerset System Support contacts**

This document should be developed and kept live.

SIMO should be getting feedback from these clinical leads with what the long term strategies are in each area.

There are a number of gaps on the list, which if we could fill would be cost saving, as it would deliver better outcomes.

### 6 Other Issues for Discussion

# 6.1 NHSE: Consultation on 2021-22 National Tariff Payment System

This is a consultation document, once the full document is finalised any medicine related information will be brought to SIMO.

Bring relevant medicine related information to SIMO. Action: SM

# 6.2 NHSE: 2021/22 priorities and operational planning guidance: Implementation guidance

-Noted

# 6.3 NHSE: Network Contract Directed Enhanced Service

-Noted

### 7 Other Issues for Noting

# 7.1 GMC: Good practice in prescribing and managing medicines and devices

-Noted.

This document clarifies that 'Prescribing' may also be used to describe any written information (information prescriptions) or advice you give to patients. This is helpful as some previously had a reluctance to only give advice. The population needs re-educating on the pharmacy first agenda.

# 7.2 UEA: Anticholinergic calculator and survey – invitation to access the tool and provide feedback

-Noted.

This has been optimised for America but may be of worth as part of medication reviews.

FV to share with other PCN pharmacists if it will be useful. Action: FV

### 8 Partners – 2021 Medicines Optimisation priorities

### 8.1 **CCG**

-Noted.

The CCG scorecard has a mix of quality, safety and cost effectiveness indicators to drive and engage primary care outside of QOF and enhanced services.

### 8.2 **LPC**

Focus:

- Discharge Medicines Service YDH NHSFT is up and running and Musgrove Hospital is on track for the early autumn.
- · CPCS GP referral pathway.
- Electronic Repeat Dispensing Somerset is one of the worst for volume. Currently working with a couple PCNs to effectively implement ERD.

### 8.3 **YDH**

AP not present.

### 8.4 SomersetFT

Mental Health Focus (SDB):

- Continue to provide clinical service and develop to be equitable across the system.
- Roll out of Electronic Prescribing Having the same system across SomersetFT would free up resources.
- Electronic transfer of prescriptions.
- Deprescribing projects STOMP

# Hospital Focus (MA):

- Succession plan of who will take over from MA.
- Recruitment and expansion 6 pharmacists will be starting in July.

#### 8.5 PCN

FV informed SIMO that the PCN pharmacists are trying to unify the way they are working. This includes forming a standard model which they can elaborate further.

### 9 System Medicines Optimisation Work Stream Feedback

# 9.1 Antimicrobial system strategy

AZ attended SIMO to present the antimicrobial system strategy on behalf of the three key organisations (Somerset NHSFT, YDH NHSFT and Somerset CCG).

The presentation showed the many successful work streams that have been put in place within the Trusts and CCG working towards their joint agenda:

- Compliance with Somerset antimicrobial prescribing guidance
- Sepsis awareness
- Reduction of dipstick testing in elderly
- Reduction of Trimethoprim prescribing in over 70s
- Outperformed on the Antimicrobial targets (Somerset one of the best)

### Priorities going forward:

- Increased workforce
- Educating people of Somerset around AMS (Public engagement)
- Cost prevention and better patient outcomes.

The presentation was noted and well regarded by the committee. SDB noted that dental was not represented within the data and is an area we need to start working with.

AZ was thanked for his attendance and presentation.

# 9.2 Work stream suggestions for the next meeting

SIMO decided that a Digital update from Andrew Prowse, David Chalkley, Justin Harrington & Alison Nation would be the best option for the next meeting.

**Action: SG** 

Ask the digital team to present at June meeting.

Other possibilities for future meetings: Medicines Safety Officers, Mental Health Team.

## 10 Regional Medicines Value Work Stream

Not discussed this meeting.

# 11 Risks Review and Management

Not discussed this meeting.

# 12 Any other business

# **Mark Ashley Retirement**

This meeting is the last that Mark Ashley will be attending as he is retiring. MA suggested that AZ should be invited in his place.

**Action: ZTW** 

AT & SG thanked him for his contributions and wished him all the best.

Invite AZ to future meetings.

### **DATE OF NEXT MEETINGS**

9<sup>th</sup> June 2021 11<sup>th</sup> August 2021 13<sup>th</sup> October 2021 8<sup>th</sup> December 2021